779 patents
Page 24 of 39
Utility
Apixaban Formulations
20 May 21
Apixaban pharmaceutical formulation is provided.
Sherif Ibrahim Farag BADAWY, Timothy D. STEVENS, Daniel KUNTZ, Brett WAYBRANT
Filed: 15 Apr 19
Utility
Method of treating a proliferative disease
18 May 21
The present invention relates to a method of treating a patient with a serine/threonine kinase inhibitor wherein resistance to the treatment with a serine/threonine kinase inhibitor is suppressed by administering the serine/threonine kinase inhibitor on an intermittent dosing schedule.
Darrin Stuart, Meghna Das Thakur
Filed: 9 Nov 12
Utility
Crystalline form of an avibactam derivative
18 May 21
A crystalline form of an avibactam derivative, pharmaceutical compositions thereof, and the use of the crystalline avibactam derivative for treating bacterial infections are provided.
Sami Karaborni
Filed: 10 Mar 20
Utility
Designer osteogenic proteins
18 May 21
The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor.
Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
Filed: 6 Dec 18
Utility
Stable Aqueous Antibody Formulation
6 May 21
The present invention relates to the field of pharmaceutical formulations of antibodies.
REBECCA LEE INGRAM, SARAH ELIZABETH WEISER
Filed: 6 Jan 21
Utility
Streptococcus Pneumoniae Capsular Polysaccharides and Conjugates Thereof
29 Apr 21
The invention relates to isolated Streptococcus pneumoniae serotype 15B capsular polysaccharide and processes for their preparation.
Mingming Han, Avvari Krishna Prasad, David Cooper, Wendy Jo Watson
Filed: 17 Dec 20
Utility
Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
27 Apr 21
Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
Filed: 21 Aug 20
Utility
Engineered Polypeptide Conjugates and Methods for Making Thereof Using Transglutaminase
22 Apr 21
The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents.
Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David SHELTON, Shu-Hui LIU, Jaume PONS, Russell DUSHIN
Filed: 18 Nov 20
Utility
Methods of Glycoengineering Proteoglycans with Distinct Glycan Structures
22 Apr 21
Disclosed herein are methods of generating proteoglycans with distinct glycan structures in engineered, non-naturally occurring eukaryotic cells.
Michelle Chang, Leonid A. Gaydukov, Giyoung Jung, Nevin M. Summers, Timothy Kuan-Ta Lu, Ron Weiss, John Scarcelli, Richard Cornell, Jeffrey Marshall, Bruno Figueroa, Wen Allen Tseng
Filed: 20 Jun 19
Utility
N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors
13 Apr 21
Brian Stephen Gerstenberger, Andrew Christopher Flick, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, Jr., Mark Edward Schnute, Daniel Wei-Shung Kung, Daniel Copley Schmitt, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
Filed: 20 Sep 19
Utility
Diacylglycerol Acyl Transferase 2 Inhibitor
8 Apr 21
David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
Filed: 5 Oct 20
Utility
Diacylglycerol Acyl Transferase 2 Inhibitor
8 Apr 21
David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
Filed: 5 Nov 20
Utility
Aqueous Pharmaceutical Formulation Comprising ANTI-PD-L1 Antibody Avelumab
8 Apr 21
The present invention relates to a novel anti-PD-L1 antibody formulation.
Gianluca RINALDI, Alessandra DEL RIO, Silvia FRATAR-CANGELI, Senta VOSS, Markus WEIGANDT
Filed: 9 Dec 20
Utility
Neisseria Meningitidis Compositions and Methods Thereof
8 Apr 21
In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2.
Annaliesa Sybil Anderson, Rasappa Gounder Arumugham, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Kathrin Ute Jansen, Thomas Richard Jones, Lakshmi Khandke, Bounthon Loun, John Lance Perez, Gary Warren Zlotnick
Filed: 18 Dec 20
Utility
ANTI-CXCR5 Antibodies and Compositions and Uses Thereof
8 Apr 21
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5.
Rachel Groth, William Brian Snyder, Xianjun Cao, Robert Joseph Dunn, Joseph Dal Porto, Michael Karin
Filed: 20 Nov 20
Utility
Tissue Factor Pathway Inhibitor Antibodies and Uses Thereof
8 Apr 21
The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof.
Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
Filed: 24 Nov 20
Utility
Pyrrolo[2,3-d]pyrimidine derivatives
6 Apr 21
Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.
Michael L. Vazquez, Neelu Kaila, Jamison B. Tuttle, Patrick Robert Verhoest, Matthew R. Reese, Karen J. Coffman, Tarek Samad, James M. Duerr, Simone Sciabola, Mihir D. Parikh
Filed: 10 Aug 15
Utility
Macrocyclic compounds as ROS1 kinase inhibitors
6 Apr 21
Steven W. Andrews, James F. Blake, Julia Haas, Gabrielle R. Kolakowski
Filed: 26 Nov 18
Utility
Stability-modulating linkers for use with antibody drug conjugates
6 Apr 21
The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.
Russell George Dushin, Pavel Strop, Magdalena Grazyna Dorywalska, Ludivine Moine
Filed: 14 Aug 15
Utility
Cyclopentane-based modulators of STING (stimulator of interferon genes)
6 Apr 21
Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
Filed: 4 Dec 19